Stiripentol

Cysolvia® is one of brands under Miedykol® a high-end and certified active pharmaceutical ingredients (APIs) and pharmaceutical intermediates manufacturer in China, mainly providing various APIs products and customized production (CMO/CDMO). We produce the stiripentol (and its intermediate products) which was developed earlist by the French company Biocodex and approved by FDA, an aromatic allylic alcohol drug for treating epileptic seizure concerned with Dravet syndrome. Its mechanism of action is its inhibitory action on CYP enzymes and enhancement of gamma-aminobutyric acid (GABA) neurotransmission. According to the latest scientific report, stiripentol has been found effective in inhibition of cancer cells. At Miedykol, we produce the innovative and market much-needed active ingredient products for special disease drugs managing arrhythmia, convulsion, postmenopausal osteoporosis, etc.. We also support your healthcare project and clinical therapies with the tailored production and integrative preparation solutions. Reach out to us for further information.